[go: up one dir, main page]

WO2011153243A3 - Anti-angiogenesis therapy for treating gastric cancer - Google Patents

Anti-angiogenesis therapy for treating gastric cancer Download PDF

Info

Publication number
WO2011153243A3
WO2011153243A3 PCT/US2011/038765 US2011038765W WO2011153243A3 WO 2011153243 A3 WO2011153243 A3 WO 2011153243A3 US 2011038765 W US2011038765 W US 2011038765W WO 2011153243 A3 WO2011153243 A3 WO 2011153243A3
Authority
WO
WIPO (PCT)
Prior art keywords
gastric cancer
treating gastric
angiogenesis therapy
angiogenesis
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/038765
Other languages
French (fr)
Other versions
WO2011153243A2 (en
Inventor
Dimitrios Georg Chondros
Barbara Mueller
Eric Hedrick
Florin Sirzen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Publication of WO2011153243A2 publication Critical patent/WO2011153243A2/en
Publication of WO2011153243A3 publication Critical patent/WO2011153243A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed herein are methods and compositions comprising anti-VEGF antibodies for use in the treatment of gastric cancer.
PCT/US2011/038765 2010-06-02 2011-06-01 Anti-angiogenesis therapy for treating gastric cancer Ceased WO2011153243A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35079810P 2010-06-02 2010-06-02
US61/350,798 2010-06-02

Publications (2)

Publication Number Publication Date
WO2011153243A2 WO2011153243A2 (en) 2011-12-08
WO2011153243A3 true WO2011153243A3 (en) 2012-01-19

Family

ID=44627141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/038765 Ceased WO2011153243A2 (en) 2010-06-02 2011-06-01 Anti-angiogenesis therapy for treating gastric cancer

Country Status (1)

Country Link
WO (1) WO2011153243A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104292330B (en) * 2013-03-08 2017-07-14 上海赛伦生物技术股份有限公司 A kind of high human anti-VEGF antibody of stability and its application
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
TWI639430B (en) * 2016-08-27 2018-11-01 中國醫藥大學 Use of pharmaceutical composition for manufacturing drug of treating gastric cancer
MX2020009152A (en) 2018-03-02 2020-11-09 Kodiak Sciences Inc IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF.
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHODS OF TREATING AN EYE DISORDER

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20090099344A1 (en) * 2003-07-28 2009-04-16 Fahrner Robert L Reducing protein a leaching during protein a affinity chromatography

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
ATE164395T1 (en) 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
ATE207080T1 (en) 1991-11-25 2001-11-15 Enzon Inc MULTIVALENT ANTIGEN-BINDING PROTEINS
DE69334255D1 (en) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker for cancer and biosynthetic binding protein for it
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
HU221343B1 (en) 1992-10-28 2002-09-28 Genentech Inc Use of anti-vegf antibodies for the treatment of cancer
PL174721B1 (en) 1992-11-13 1998-09-30 Idec Pharma Corp Monoclonal antibody anty-cd2
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
EP1516628B1 (en) 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
EP1787999B1 (en) 1997-04-07 2010-08-04 Genentech, Inc. Anti-VEGF antibodies
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
JP2001521909A (en) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ES2292236T3 (en) 1998-04-02 2008-03-01 Genentech, Inc. VARIATIONS OF ANTIBODIES AND THEIR FRAGMENTS.
DK1071700T3 (en) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity
CN1763097B (en) 1999-01-15 2011-04-13 杰南技术公司 Polypeptide variants with altered effector function
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
LT2857516T (en) 2000-04-11 2017-09-11 Genentech, Inc. Multivalent antibodies and uses therefor
JP4336498B2 (en) 2000-12-12 2009-09-30 メディミューン，エルエルシー Molecules with extended half-life and compositions and uses thereof
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DK1443961T3 (en) 2001-10-25 2009-08-24 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
RS20181002A1 (en) 2003-05-30 2018-12-31 Genentech Inc Treatment with anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20090099344A1 (en) * 2003-07-28 2009-04-16 Fahrner Robert L Reducing protein a leaching during protein a affinity chromatography

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"793 Salvage therapy with bevacizumab, capecitabin, and mitomycin C (BECAM) for patients with metastatic colorectal or gastric cancer refractory to 5-fluorouracil, oxaliplatin, irinotecan, and cetuximab", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 3, no. 2, 1 October 2005 (2005-10-01), pages 226, XP005132907, ISSN: 1359-6349 *
B. F. EL-RAYES ET AL: "A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers", ANNALS OF ONCOLOGY, vol. 21, no. 10, 23 March 2010 (2010-03-23), pages 1999 - 2004, XP055012999, ISSN: 0923-7534, DOI: 10.1093/annonc/mdq065 *
CATALANO V ET AL: "Gastric cancer", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 71, no. 2, 1 August 2009 (2009-08-01), pages 127 - 164, XP026251198, ISSN: 1040-8428, [retrieved on 20090220], DOI: 10.1016/J.CRITREVONC.2009.01.004 *
JAVLE MILIND ET AL: "Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, vol. 3, no. 1, 23 March 2010 (2010-03-23), pages 11, XP021083337, ISSN: 1756-8722, DOI: 10.1186/1756-8722-3-11 *
KELSEN D ET AL: "Analysis of survival with modified docetaxel, cisplatin, fluorouracil, and bevacizumab in patients with metastatic gastroesophageal adenocarcinoma: Results of a phase II clinical trial", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 27, 1 January 2009 (2009-01-01), pages 4512, XP009154355, ISSN: 0732-183X *
MORABITO A ET AL: "Systemic treatment of gastric cancer", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 70, no. 3, 1 June 2009 (2009-06-01), pages 216 - 234, XP026104335, ISSN: 1040-8428, [retrieved on 20081001], DOI: 10.1016/J.CRITREVONC.2008.08.005 *
NINOMIYA S ET AL: "Effect of Bevacizumab, a Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, on Peritoneal Metastasis of MNK-45P Human Gastric Cancer in Mice", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 154, no. 2, 15 June 2009 (2009-06-15), pages 196 - 202, XP026151213, ISSN: 0022-4804, [retrieved on 20080916], DOI: 10.1016/J.JSS.2008.08.017 *
SHAH MANISH A ET AL: "Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 NOV 2006 LNKD- PUBMED:17114652, vol. 24, no. 33, 20 November 2006 (2006-11-20), pages 5201 - 5206, XP009154389, ISSN: 1527-7755 *

Also Published As

Publication number Publication date
WO2011153243A2 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
IL279330A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
IL276434A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014031487A8 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
MX2011010955A (en) Adjuvant cancer therapy.
IL225471A0 (en) Compositions and methods for the prevention and treatment of cancer
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
EP2651443A4 (en) Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration
WO2012006634A3 (en) Prostate specific antigen (psa) peptide therapy
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
MX2014001766A (en) Neuregulin antibodies and uses thereof.
SMT201700387T1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2012061413A3 (en) Isoflavonoid compositions and methods for the treatment of cancer
WO2011153243A3 (en) Anti-angiogenesis therapy for treating gastric cancer
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use
EP2590712A4 (en) System and method for hyperthermic tumor treatment
WO2011031833A3 (en) Human anti-cancer antibodies
HK40110865A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK40087661A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2011133480A3 (en) Method of treating gastric cancer
HK40092402A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK1189502A (en) Compositions and methods for the prevention and treatment of cancer
HK1213581A1 (en) Anti-cd40 antibodies and methods of use
HK1195925A (en) Methods and compositions for the treatment and diagnosis of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11726014

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11726014

Country of ref document: EP

Kind code of ref document: A2